Exogenus is developing promising therapeutics for the treatment of chronic and acute wounds, among which are diabetic foot ulcers, some of the most debilitating and hard-to-heal.

The lead technology licensed and under development by Exogenus for the treatment of wounds, is owned by Crioestaminal and Biocant, and relates to the use of exosomes secreted by cells of the Umbilical Cord Blood to promote wound healing.  Part of the proof-of-concept data was presented in the 14th Portuguese Congress of Diabetes (http://www.diabetologia2018.com/), and its potential has been recognized in press: